Asensus Surgical, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-11-14: Form 8-K; Period of report 2022-11-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-08-11: Form 8-K; Period of report 2022-08-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-06-14: Form 8-K; Period of report 2022-06-14; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2022-05-10: Form 8-K; Period of report 2022-05-10; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-11-14 | 8-K | 2022-11-10 | 2.02 Results of Operations and Financial Condition | 2.02 On November 10, 2022, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2022. | asxc20221110_8k.htm |
| 2022-08-11 | 8-K | 2022-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2022, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2022. | asxc20220809_8k.htm |
| 2022-06-14 | 8-K | 2022-06-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 14, 2022, Asensus Surgical, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). | asxc20220614_8k.htm |
| 2022-05-10 | 8-K | 2022-05-10 | 8.01 Other Events | 8.01 As previously reported by Asensus Surgical, Inc. (the “Company”), the Company has entered into a Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc., dated May 19, 2021 and amended on March 18, 2022 (the “Agreement”), for the sale of up to $100,000,000 in shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in an “at the market offering” pursuant to the Agreement. | transe20220509_8k.htm |
| 2022-05-05 | 8-K | 2022-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2022, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2022. | transe20220504_8k.htm |
| 2022-03-18 | 8-K | 2022-03-18 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | transe20220317_8k.htm |
| 2022-03-15 | 8-K | 2022-03-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 10, 2022, Jane Hsiao, Ph.D., a member of the Board of Directors of Asensus Surgical, Inc. (the “Company”) since 2005, informed the Company that she would not stand for re-election to the Board because of other commitments. | transe20220314_8k.htm |
| 2022-03-02 | 8-K | 2022-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2022, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2021. | transe20220301_8k.htm |
| 2022-02-07 | 8-K | 2022-02-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 2, 2022, the independent members of the Board of Directors (the “Board”) of Asensus Surgical, Inc. (the “Company”), upon the recommendation of the Compensation Committee (the “Committee”) of the Board approved the 2021 incentive bonuses, retention bonuses and compensation changes for 2022 for Anthony Fernando, the CEO, and Shameze Rampertab, the CFO, of the Company. | transe20220207_8k.htm |
| 2022-01-13 | 8-K | 2022-01-13 | 7.01 Regulation FD Disclosure | 7.01 On January 13, 2022, Asensus Surgical, Inc. (the “Company”) is making a corporate presentation that provides a current overview about the Company to participants at the 40th Annual J.P. Morgan Healthcare Conference. | transe20220111_8k.htm |
| 2022-01-10 | 8-K | 2022-01-10 | 8.01 Other Events | 8.01 On January 10, 2022, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing an update with preliminary financial results for the fourth quarter and full year ended December 31, 2021. | transe20220107_8k.htm |